IP Library Granted Patent US 11,179,405
Granted Patent B2
US 11,179,405 · App. 16/328,782 · Granted Nov 23, 2021

Nutritional compositions for infants and/or young children comprising oligosaccharides

Inventors: Bernard Berger (Maracon, CH); Norbert Sprenger (Savigny, CH); Dominik Grathwohl (Lausanne, CH)
Assignee: Societe des Produits Nestle S.A.
A61K31/702A23L33/21A23L33/40A61K9/0056A61K9/0095A61K45/06A61P1/00A61P31/04A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,179,405
App. No.
16/328,782
Granted
Nov 23, 2021
Kind
B2
Abstract

The present invention relates to nutritional compositions for infants or young children and their health effects, that comprise at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide. These nutritional compositions are for use to prevent and/or treat infection in an infant or young child, by promoting and/or reducing specific microbiota communities in an infant or young child.

Claims (30)

1. A method to reduce or decrease an incidence of and/or treat infection by promoting a Community type B and/or by reducing a Community type C in an infant or young child in need thereof, wherein the Community type B is defined as a microbiota community comprising greater than 80% Bifidobactera (% relative abundance), and the Community type C is defined as a microbiota community comprising from 50 to 80% Bifidobacteria (% relative abundance) and further comprising one or more of Firmicutes, Bacteroidetes and/or Proteobacteria, the method comprising:

administering a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide to the infant or young child,

wherein the at least one fucosylated oligosaccharide is in a total amount of 0.8-1.5 g/L of the nutritional composition and/or in a total amount of 0.62-1.16 g/100 g of the nutritional composition on a dry weight basis; and/or the at least one N-acetylated oligosaccharide is in a total amount of 0.5-0.8 g/L of the nutritional composition and/or in a total amount of 0.39-0.62 g/100 g of the nutritional composition on a dry weight basis,

wherein the infant or young child is being treated by antibiotic and/or has been treated by antibiotic, and

wherein the promoting of the Community type B and/or the reducing of the Community type C is in comparison to microbiota in the gut of infants or young children fed predominantly or exclusively with a conventional nutritional composition not comprising the at least one fucosylated oligosaccharide and the at least one N-acetylated oligosaccharide,

wherein the nutritional composition reduces or decreases an incidence of and/or treats infection 2 weeks to 12 months after termination of the administering of the nutritional composition.

2. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide is selected from the group consisting of 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and any combination thereof.

3. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide comprises 2′-fucosyllactose, and the at least one N-acetylated oligosaccharide comprises lacto-N-neotetraose (LNnT).

4. The method according to claim 1 , wherein the nutritional composition is in a form selected from the group consisting of an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a preterm formula, a baby food, an infant cereal composition, a fortifier and a supplement.

5. The method according to claim 1 , wherein the infant or young child is under 6 months of age.

6. The method according to claim 1 , wherein the infant or young child is selected from the group consisting of preterm infants, infants born by Caesarean-section, infants born small for gestational age or with low birth weight, hospitalized infants/young children, infants/young children treated or having been treated by antibiotics, and infants/young children suffering or having suffered from gut infection and/or gut inflammation.

7. The method according to claim 1 , wherein the nutritional composition reduces fever and/or use of antipyretics in the infant or young child.

8. A method for reducing fever caused by infection and/or reducing administration of antipyretics in an infant or young child, the method comprising:

administering a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide, wherein the at least one fucosylated oligosaccharide is in a total amount of 0.8-1.5 g/L of the nutritional composition and/or in a total amount of 0.62-1.16 g/100 g of the nutritional composition on a dry weight basis; and the at least one N-acetylated oligosaccharide is in a total amount of 0.5-0.8 g/L of the nutritional composition and/or in a total amount of 0.39-0.62 g/100 g of the nutritional composition on a dry weight basis to the infant or young child in need of same,

wherein the infant or young child is being treated by and antibiotic and/or has been treated by an antibiotic,

wherein the nutritional composition reduces or decreases an incidence of and/or treats infection 2 weeks to 12 months after termination of the administering of the nutritional composition.

9. The method according to claim 8 , wherein the at least one fucosylated oligosaccharide is selected from the group consisting of 2′-fucosyllactose, 3′ fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and combinations thereof.

10. The method according to claim 8 , wherein the at least one fucosylated oligosaccharide comprises 2′-fucosyllactose, and the at least one N-acetylated oligosaccharide comprises lacto-N-neotetraose (LNnT).

11. The method according to claim 8 , wherein the nutritional composition is in a form selected from the group consisting of an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a preterm formula, a baby food, an infant cereal composition, a fortifier and a supplement.

12. The method according to claim 8 , wherein the infant or young child is under 6 months of age.

13. The method according to claim 8 , wherein the infant or young child is selected from the group consisting of preterm infants, infants born by Caesarean-section, infants born small for gestational age or with low birth weight, hospitalized infants/young children, infants/young children treated or having been treated by antibiotics, and infants/young children suffering or having suffered from gut infection and/or gut inflammation.

14. A method for reducing or decreasing an incidence of and/or treating diseases/conditions involving (i) fever caused by infection and/or (ii) administration of antibiotics and/or (iii) administration of antipyretics in an infant or young child in need thereof, the method comprising:

administering to the infant or young child a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide, wherein the at least one fucosylated oligosaccharide is in a total amount of 0.8-1.5 g/L of the nutritional composition and/or in a total amount of 0.62-1.16 g/100 g of the nutritional composition on a dry weight basis; and the at least one N-acetylated oligosaccharide is in a total amount of 0.5-0.8 g/L of the nutritional composition and/or in a total amount of 0.39-0.62 g/100 g of the nutritional composition on a dry weight basis,

wherein the infant or young child is being treated by an antibiotic and/or has been treated by an antibiotic,

wherein the nutritional composition reduces or decreases an incidence of and/or treats infection 2 weeks to 12 months after termination of the administering of the nutritional composition.

15. The method according to claim 14 , wherein the at least one fucosylated oligosaccharide is selected from the group consisting of 2′-fucosyllactose, 3′ fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and combinations thereof.

16. The method according to claim 14 , wherein the at least one fucosylated oligosaccharide comprises 2′-fucosyllactose, and the at least one N-acetylated oligosaccharide comprises lacto-N-neotetraose (LNnT).

17. The method according to claim 14 , wherein the nutritional composition is in a form selected from the group consisting of an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a preterm formula, a baby food, an infant cereal composition, a fortifier and a supplement.

18. The method according to claim 14 , wherein the infant or young child is under 6 months of age.

19. The method according to claim 14 , wherein the infant or young child is selected from the group consisting of preterm infants, infants born by Caesarean-section, infants born small for gestational age or with low birth weight, hospitalized infants/young children, infants/young children treated or having been treated by antibiotics, and infants/young children suffering or having suffered from gut infection and/or gut inflammation.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2021
From: BERGER, BERNARD; SPRENGER, NORBERT; GRATHWOHL, DOMINIK
To: NESTEC S.A.
Reel/Frame 057143/0104 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
Priority Claims (1)
EP 16187699 · Sep 7, 2016 · regional
Continuity (1)
Related Publication 20190209593A1 · Jul 11, 2019